There could be some interesting partnerships coming up...
We don't know much, but I would guess they are doing some cooperative research based on a joint development agreement. If the research pans out, they will enter into a license.
This solves the mystery of the feasibility study for a "mu opioid receptor antagonist" listed in TTNP's most recent corporate presentation. Basically, this is a six month (or maybe even one year) implant of naltexetone (e.g. Vivitrol).
Now, as for the kappa opioid receptor agonist for neuropathic pain also mentioned as being in a feasibility study, I bet they are partnering with someone on that as well.
Same with liraglutide (Victoza) for type 2 diabetes,
News 
Market Data 
Discover 
